Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$26.37
$0.40(1.28%)
At close: 4:00 PM EDT
$26.37
$0.40(1.28%)
Day’s Range― - ―
52-Week Range$16.10 - $33.07
Previous Close$31.59
Volume994.73K
Average Volume (3M)1.17M
Market Cap
$2.18B
Enterprise Value$2.16B
Total Cash (Recent Filing)$152.63M
Total Debt (Recent Filing)$26.97M
Price to Earnings (P/E)29.3
Beta0.67
Next Earnings
Nov 04, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding76,726,800
10 Day Avg. Volume1,094,752
30 Day Avg. Volume1,166,629
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit6.70
Enterprise Value/Ebitda16.99
Forecast
1Y Price Target
$34.00Price Target Upside28.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)1.29
Revenue Forecast (FY)$1.37B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Profit GrowthProgyny has delivered substantial multi-year revenue expansion while improving both net and operating margins. This combination indicates increasing scale and operating discipline, strengthening its ability to reinvest in its fertility-benefits platform and support durable earnings growth.
Strong Cash Generation And LiquidityHigh operating and free cash flow provide internal funding for technology, network development, and client support without relying heavily on external capital. Strong cash conversion also gives Progyny flexibility to manage investment needs and return capital while preserving financial resilience.
Employer Adoption And Client RetentionNew-life additions, strong retention, and expansion among large employers support the durability of Progyny’s contracted, employer-sponsored model. A growing covered population can widen the platform’s network value and create a larger base for recurring benefit administration revenue.
Bears Say
Moderating Growth OutlookAlthough underlying growth remains positive, reported expansion is moderating compared with Progyny’s earlier growth profile and is affected by the transition-client comparison. Slower top-line growth could limit operating leverage and place greater importance on retention, selling execution, and productivity.
Moderate Gross MarginA moderate gross margin leaves less room to absorb changes in service utilization, benefit costs, or investment intensity than a higher-margin model would provide. Sustaining profitability therefore depends on continued care-management efficiencies and disciplined operating expense management.
Active Competitive EnvironmentCompetition creates ongoing pressure to defend existing employer accounts and win replacement opportunities, potentially increasing sales effort and client-acquisition costs. Progyny’s ability to preserve retention and differentiate its integrated clinical, pharmacy, and navigation offering remains important to durable growth.
Progyny News
PGNY FAQ
What was Progyny’s price range in the past 12 months?
Progyny lowest stock price was $16.10 and its highest was $33.06 in the past 12 months.
What is Progyny’s market cap?
Progyny’s market cap is $2.18B.
When is Progyny’s upcoming earnings report date?
Progyny’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.
How were Progyny’s earnings last quarter?
Progyny released its earnings results on Aug 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.335 by $0.005.
Is Progyny overvalued?
According to Wall Street analysts Progyny’s price is currently Undervalued.
Does Progyny pay dividends?
Progyny does not currently pay dividends.
What is Progyny’s EPS estimate?
Progyny’s EPS estimate is 0.31.
How many shares outstanding does Progyny have?
Progyny has 76,726,800 shares outstanding.
What happened to Progyny’s price movement after its last earnings report?
Progyny reported an EPS of $0.34 in its last earnings report, beating expectations of $0.335. Following the earnings report the stock price went down -6.984%.
Which hedge fund is a major shareholder of Progyny?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (28.93% Upside)
$34.00 (28.93% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 163.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $321.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.52%
12-Months-Change
Fundamentals
Return on Equity
15.98%
Trailing 12-Months
Asset Growth
-5.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Progyny
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
PGNY Company Deck
PGNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong financial and operational positives: record quarterly results, margin expansion, robust operating cash flow ($201M TTM), a clean balance sheet, sizable share repurchases, and meaningful early sales momentum with confidence to add 1M+ lives. The primary negatives were a slightly more pronounced summer seasonality that tempered near-term visibility and required modest guidance recalibration, comparability noise from a prior transition client, and early-stage nature of new channels (Progyny Select). Overall the positive financial performance, cash generation, and sales/retention momentum materially outweigh the transitory seasonality and execution timing risks described.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$34.00
▲(28.93% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
33.06% Mutual Funds
2.35% Other Institutional Investors
27.81% Public Companies and
Individual Investors